Please login to the form below

Not currently logged in
Email:
Password:

malaria

This page shows the latest malaria news and features for those working in and with pharma, biotech and healthcare.

Evotec says Sanofi deal makes it anti-infectives powerhouse

Evotec says Sanofi deal makes it anti-infectives powerhouse

regulatory approvals of course – and that will give it “the highest qualified translational footprint in infectious disease research globally.”It will focus initially on antimicrobial resistant (AMR) infections, tuberculosis, and malaria,

Latest news

More from news
Approximately 22 fully matching, plus 110 partially matching documents found.

Latest Intelligence

  • Waking the sleeping giant Waking the sleeping giant

    In Uganda, a malaria-specific app provides questions and answers relating to that disease, while in Mozambique another app greatly increases the efficacy of immunisation programmes by reminding users via text

  • The three forces behind the re-imagining of patient care The three forces behind the re-imagining of patient care

    developing a device that can detect malaria and give you a result in two minutes.

  • Opening up innovation Opening up innovation

    For GlaxoSmithKline its pharma open innovation efforts began with diseases of the developing world, such as malaria - where it offered researchers free access to a 'virtual library' of tens of thousands

  • Aiming high for women Aiming high for women

    6. Halt and start to reverse the spread and incidence of HIV/AIDS, malaria and other diseases - MISSED, although the number of new HIV/AIDS infections fell by 40% in

  • Deal Watch February 2016 Deal Watch February 2016

    Alere has annual sales of approximately $2.5bn from a portfolio of point-of-care products in areas including cardiometabolic, infectious diseases such as HIV, malaria, syphilis, E. ... acquisition - company. 7, 200. Alere/Abbott Laboratories. portfolio

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest appointments

  • Former PEPFAR head Mark Dybul to lead the Global Fund Former PEPFAR head Mark Dybul to lead the Global Fund

    Former PEPFAR head Mark Dybul to lead the Global Fund. Joins at time of change for the AIDS, tuberculosis and malaria focused non-profit organisation. ... The Global Fund to Fight AIDS, Tuberculosis and Malaria has appointed renowned AIDS expert Dr Mark

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics